Evidence map›Paper›PMID 27617336›Full record

ArticleImmunologic research2016

Suppression of interleukin 17 contributes to the immunomodulatory effects of adipose-derived stem cells in a murine model of systemic lupus erythematosus.

Xiaoliang He, Yunlong Zhang, Ai Zhu, Kang Zeng, Xiuping Zhang, Li Gong, Yusheng Peng, Kuan Lai, Shaogang Qu

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. The role of miRNAs in Behçet's disease.Frontiers in immunology · 2023
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. CDK4/6 inhibitor palbociclib reduces inflammation in lupus-prone mice.American journal of clinical and experimental urology · 2021
    Article
  9. Article
  10. Review
  11. Article
  12. Stem cell-based treatment of kidney diseases.Experimental biology and medicine (Maywood, N.J.) · 2020
    Review
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Xiaoliang HeDepartment of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, People's Republic of China.
Yunlong ZhangDepartment of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, People's Republic of China.
Ai ZhuDepartment of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, People's Republic of China.
Kang ZengDepartment of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People's Republic of China.
Xiuping ZhangTeaching Center of Experimental Medicine, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, People's Republic of China.
Li GongExperimental Animal Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People's Republic of China.
Yusheng PengDepartment of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People's Republic of China.
Kuan LaiDepartment of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People's Republic of China. kuan_lai@163.com.
Shaogang QuDepartment of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, People's Republic of China. sgq9528@163.com.
Southern Medical University · CNNanfang Hospital · CNThird Affiliated Hospital of Southern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to roles in immunoregulation and low immunogenicity, mesenchymal stem cells have been suggested to be potent regulators of the immune response and may represent promising treatments for autoimmune disease. Adipose-derived stem cells (ADSCs), stromal cells derived from adipose tissue, were investigated with allogeneic ADSCs in B6.MRL/lpr mice, a murine model of systemic lupus erythematosus (SLE). We intravenously injected allogeneic ADSCs into SLE mice after disease onset and report that ADSCs reduced anti-ds DNA antibodies in serum and proteinuria in SLE mice. Also, ADSCs decreased IL-17 and IL-6 expression in serum of SLE mice. ADSCs alleviated renal damage and inflammatory cell infiltration and edema of the renal interstitium. Furthermore, ADSCs significantly downregulated renal IL-17 and CD68 expression, suggesting that ADSCs suppressed renal inflammation. ADSCs also decreased IL-17 mRNA expression and increased Foxp3, ROR-γt and miR-23b mRNA expression in renal tissue in SLE mice. ADSCs reduced renal protein expression of TAB 2 and IKK-α in SLE mice. Thus, ADSCs may be a novel potential therapy for treating SLE.

Indexed as

Adipose TissueAnimalsAntibodies, AntinuclearAutoantibodiesCells, CulturedCoculture TechniquesDown-RegulationFemaleImmunomodulationInterleukin-17Interleukin-6KidneyLupus Erythematosus, SystemicMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMice, Inbred C57BLAntibodies, AntinuclearAutoantibodiesInterleukin-17Interleukin-6Adipose-derived stem cellsImmunomodulationInterleukin 17miR-23bSystemic lupus erythematosus

Identifiers

PMID27617336
OpenAlexW2518242356

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.